Muscular Dystrophy: Medical Treatments

Department of Health and Social Care written question – answered on 3rd July 2018.

Alert me about debates like this

Photo of Jim Shannon Jim Shannon Shadow DUP Spokesperson (Human Rights), Shadow DUP Spokesperson (Health)

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 31 May 2018 to Question 146853 on Muscular Dystrophy: Medical Treatments, what assessment his Department has made of the effect of the introduction of a cost-effectiveness threshold into NICE's high specialised technology programme on patients' access to new treatments for muscular dystrophy.

Photo of Jim Shannon Jim Shannon Shadow DUP Spokesperson (Human Rights), Shadow DUP Spokesperson (Health)

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 31 May 2018 to Question 146853, what assessment his Department has made of the effect of the introduction of a cost-effectiveness threshold into NICE's highly specialised technology programme on patients' access to new treatments for muscular dystrophy.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The changes to the National Institute for Health and Care Excellence’s (NICE) methodology for the development of highly specialised technology (HST) guidance were introduced following public consultation and create a framework that will enable truly transformative new drugs for patients with rare diseases to be made available to patients where companies are willing to set prices that fairly reflect the added benefit they bring. NICE is currently developing HST guidance on the use of eteplirsen for treating Duchenne muscular dystrophy.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.